Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
McKinsey
McKesson
Baxter
AstraZeneca

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for GDC-0623

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for GDC-0623?

GDC-0623 is an investigational drug.

There have been 165 clinical trials for GDC-0623. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2010.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Leukemia. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.

There are nine US patents protecting this investigational drug and one hundred and fifty-six international patents.

Recent Clinical Trials for GDC-0623
TitleSponsorPhase
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to HormNational Cancer Institute (NCI)Phase 1/Phase 2
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer Spread to the BonesNational Cancer Institute (NCI)Phase 2
A Study Evaluating the Efficacy and Safety of GDC-0077 + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast CancerHoffmann-La RochePhase 2/Phase 3

See all GDC-0623 clinical trials

Clinical Trial Summary for GDC-0623

Top disease conditions for GDC-0623
Top clinical trial sponsors for GDC-0623

See all GDC-0623 clinical trials

US Patents for GDC-0623

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GDC-0623   Start Trial Methods and compositions for treating abnormal cell growth Verastem, Inc. (Needham, MA)   Start Trial
GDC-0623   Start Trial 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase Genentech, Inc. (South San Francisco, CA)   Start Trial
GDC-0623   Start Trial 5-anilinoimidazopyridines and methods of use Genentech, Inc. (South San Francisco, CA)   Start Trial
GDC-0623   Start Trial Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer GENENTECH, INC. (South San Francisco, CA)   Start Trial
GDC-0623   Start Trial 5-anilinoimidazopyridines and methods of use Genentech, Inc. (South San Francisco, CA)   Start Trial
GDC-0623   Start Trial Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazole-5-yl)-5,6-dihydrobenzo[F]- imidazo [1,2-D][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof Genentech, Inc. (South San Francisco, CA)   Start Trial
GDC-0623   Start Trial Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases Genentech, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GDC-0623

Drugname Country Document Number Estimated Expiration Related US Patent
GDC-0623 European Patent Office 3102232 2034-02-07   Start Trial
GDC-0623 Hong Kong 1232152 2034-02-07   Start Trial
GDC-0623 Japan 2017505321 2034-02-07   Start Trial
GDC-0623 World Intellectual Property Organization (WIPO) 2015120289 2034-02-07   Start Trial
GDC-0623 Argentina 069803 2027-12-19   Start Trial
GDC-0623 Australia 2008343065 2027-12-19   Start Trial
GDC-0623 Brazil PI0819529 2027-12-19   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Medtronic
Johnson and Johnson
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.